Kristin Broughton, MD
Family Medicine · Derry, NHNPI 1952715401
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $422, 2.0 times the $209 reported in 2019.
Across 80 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$332
- GSK$180
- Amgen$127
- Novo Nordisk$117
- Merck$103
- Novartis$91
- plus $487 from 13 others
What the payments were for
- Food & beverage$1,437100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 16 | $332 |
| GSK | 10 | $180 |
| Amgen | 8 | $127 |
| Novo Nordisk | 7 | $117 |
| Merck | 8 | $103 |
| Novartis | 6 | $91 |
| Exact Sciences | 5 | $91 |
| AstraZeneca | 3 | $75 |
| Bayer | 2 | $62 |
| Pfizer | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Abbott | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Baxter Healthcare | 1 | $25 |
| Lilly USA, LLC | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Mylan Specialty L.p. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
How this compares
$1,437 in reported general payments places this provider in the 85th percentile of 397 family medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 47 | $36,575 |
| EliquisApixaban | 34 | $30,127 |
| JardianceEmpagliflozin | 22 | $24,339 |
| MounjaroTirzepatide | 19 | $22,766 |
| OzempicSemaglutide | 15 | $14,879 |
| MyrbetriqMirabegron | 12 | $10,500 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $9,472 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $9,106 |
| MovantikNaloxegol Oxalate | 13 | $5,155 |
| Alendronate Sodium | 33 | $3,669 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 52 | $2,721 |
| Famotidine | 49 | $2,149 |
| Levocetirizine Dihydrochloride | 26 | $1,843 |
| Tirosint-SolLevothyroxine Sodium | 11 | $1,681 |
| Levothyroxine Sodium | 155 | $1,397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $103 | $36,57547 claims |
| PfizerEliquis | $47 | $30,12734 claims |
| Boehringer IngelheimJardiance | $14 | $24,33922 claims |
| Lilly USA, LLCMounjaro | $22 | $22,76619 claims |
| Novo NordiskOzempic | $117 | $14,87915 claims |
| GSKTrelegy Ellipta | $180 | $9,47211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 397 family medicine providers in New Hampshire.
Other family medicine in Derry
- Robyn StewartDerry$8K
- Douglas DrefferDerry$5K
- John WheelerDerry$5K
- John DaleyDerry$5K
- Michael MaroldaDerry$5K
- Katelyn IsherwoodDerry$3K
- Sarah MuraiDerry$2K
- Cristi EgenolfDerry$2K
- Scott LowDerry$1K
- Mark BallentynePortsmouth$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.